The three-year efficacy of iguratimod in clinical daily practice in patients with rheumatoid arthritis. Issue 5 (3rd September 2019)

• Record Type: Journal Article
• Authors: Suto, Takahito; Yonemoto, Yukio; Okamura, Koichi; Sakane, Hideo; Takeuchi, Kimihiko; Tamura, Yasuyuki; Kaneko, Tetsuya; Ayabe, Keio; Chikuda, Hirotaka
• Is Part Of: Modern rheumatology. Volume 29:Issue 5(2019)
• Page Start: 775
• Page End: 781
• Publication Date: 2019-09-03
• Subjects: Iguratimod -- DMARDs -- methotrexate -- biological treatment -- rheumatoid arthritis; Rheumatology -- Periodicals; 616.723005
• DOI: 10.1080/14397595.2018.1510879
• Languages: English
• ISSNs: 1439-7595

Abstract

Abstract: Objectives: To assess the middle-term outcome of iguratimod (IGU) in rheumatoid arthritis (RA) patients. Methods: Sixty-nine RA patients (14 males and 55 females, mean age of 64.0 years) receiving IGU-containing therapies were enrolled. We divided these patients into three groups based on the treatment at the baseline: an IGU group, a methotrexate (MTX) plus IGU group, and a biologics plus IGU group. The baseline characteristics and clinical course were evaluated over three years. Predictive factors associated with the achievement of low disease activity (LDA) were statistically analyzed. Results: The survival rate of IGU therapy at 3 years was 40.6%. The disease activity was significantly decreased in the IGU group and MTX plus IGU group compared with the baseline. Furthermore, 38 patients (55.1%) were in remission or had LDA at 3 years. The patient gender, use of prednisolone (PSL) and DAS28-CRP at baseline were the factors associated with the achievement of remission or LDA at three years. Conclusion: IGU was effective without MTX or bDMARDs as well as in combination with MTX. A female gender, no use of PSL and a low DAS28-CRP at the initiation of IGU were associated with clinical remission or LDA achievement at three years.